Vericel Corporation $VCEL Holdings Reduced by Geneva Capital Management LLC

Geneva Capital Management LLC cut its position in Vericel Corporation (NASDAQ:VCEL – Free Report) by 3.1% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,297,344 shares of the biotechnology company’s stock after selling 41,779 shares during the period. Vericel accounts for 1.5% of Geneva Capital Management LLC’s investment portfolio, making the stock its 22nd largest holding. Geneva Capital Management LLC’s holdings in Vericel were worth $52,075,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Lisanti Capital Growth LLC purchased a new stake in shares of Vericel during the 2nd quarter worth $5,356,000. Man Group plc acquired a new position in shares of Vericel during the second quarter worth $2,998,000. Scholtz & Company LLC purchased a new position in Vericel in the second quarter valued at $2,287,000. Bank of New York Mellon Corp purchased a new position in Vericel in the second quarter valued at $12,366,000. Finally, Madison Asset Management LLC purchased a new position in Vericel in the second quarter valued at $2,230,000.

Insider Transactions at Vericel

In other Vericel news, CFO Joseph Mara, Jr. sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $58.26, for a total value of $1,456,500.00. Following the completion of the sale, the chief financial officer owned 16,186 shares in the company, valued at approximately $942,996.36. The trade was a 60.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Robert Zerbe sold 2,000 shares of the stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $57.88, for a total value of $115,760.00. Following the completion of the sale, the director directly owned 32,995 shares of the company’s stock, valued at $1,909,750.60. The trade was a 5.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 49,008 shares of company stock worth $2,701,078 in the last three months. Corporate insiders own 7.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on VCEL. Wall Street Zen upgraded Vericel from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 7th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Vericel in a research report on Thursday, October 29th. Zacks Research upgraded Vericel from a “hold” rating to a “strong-buy” rating in a report on Monday, November 9th. Truist Financial raised their target price on Vericel from $52.00 to $65.00 and gave the stock a “buy” rating in a research report on Friday, November 6th. Finally, Stephens raised their target price on Vericel from $55.00 to $68.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 10th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $62.00.

Read Our Latest Report on VCEL

Vericel Stock Performance

Vericel stock opened at $56.96 on Monday. Vericel Corporation has a fifty-two week low of $28.95 and a fifty-two week high of $59.75. The company has a market capitalization of $2.91 billion, a P/E ratio of 89.00 and a beta of 1.08. The stock has a 50-day simple moving average of $42.78 and a 200-day simple moving average of $39.41.

Vericel (NASDAQ:VCEL – Get Free Report) last announced its earnings results on Thursday, November 5th. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.21. The firm had revenue of $85.37 million during the quarter, compared to analysts’ expectations of $77.95 million. Vericel had a return on equity of 9.09% and a net margin of 10.27%. The business’s revenue was up 26.5% on a year-over-year basis. During the same period in the prior year, the firm earned $0.10 EPS. As a group, analysts forecast that Vericel Corporation will post 0.78 earnings per share for the current year.

About Vericel

(Free Report)

Vericel Corporation is a biopharmaceutical company focused on developing and commercializing cell therapies and other treatments for serious conditions. Based in Cambridge, Massachusetts, the company markets its products primarily in the United States. Its products include MACI, an implant made from a patient’s own cultured cartilage cells used to repair certain cartilage defects in the knee, and Epicel, a cultured skin graft used to treat patients with deep burns. Vericel also commercializes NexoBrid in the United States, an enzyme-based treatment for removing dead tissue from severe thermal burns.

See Also

Want to see what other hedge funds are holding VCEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vericel Corporation (NASDAQ:VCEL – Free Report).

Institutional Ownership by Quarter for Vericel (NASDAQ:VCEL)

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.